To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer

NCT06352008 ↗

Phase 2 Recruiting 64 enrolled Tianjin Medical University Cancer Institute and Hospital

NaSingle-groupOpen-labelTreatment

Summary

To explore the effectiveness of anlotinib hydrochloride capsule in postoperative non-pCR non-small cell lung cancer patients with adjuvant intensive therapy

Timeline

Start: 2024-07-01
Primary completion: 2026-06-01
Completion: 2027-06-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	12 mg	Oral

To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer

Summary

Timeline

Drugs

Indications